US2009247487A1PendingUtilityA1

Combination Therapy to Treat Hepatitis B Virus

61
Assignee: GILEAD SCIENCES INCPriority: Nov 2, 1998Filed: Jun 12, 2009Published: Oct 1, 2009
Est. expiryNov 2, 2018(expired)· nominal 20-yr term from priority
Inventors:Phillip A. FurmanGeorge R. Painter, IiiDavid W. BarryFranck Rousseau
A61P 31/12A61P 35/00A61P 31/20A61P 31/14A61P 1/16A61K 45/06A61K 31/66A61K 31/52A61K 31/70A61K 31/675A61K 31/513
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of β-2 hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of famciclovir and Bis-POM-PMEA. 
   
   
       2 . The method of  claim 1 , wherein the β-FTC is in the form of the (−)-optical isomer. 
   
   
       3 . The method of  claim 1 , wherein the second anti-hepatitis B agent is famciclovir. 
   
   
       4 . The method of  claim 1 , wherein the second anti-hepatitis B agent is Bis-POM-PMEA. 
   
   
       5 . A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising an effective amount of β-2-hydroxymethyl-5 -(5-fluorocytosin-1-yl)-1,3 oxathiolane (β-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof in a synergistic combination with an effective amount of a second anti-hepatitis B agent selected from the group consisting of famciclovir and Bis-POM-PMEA. 
   
   
       6 . The composition of  claim 5 , wherein the β-FTC is in the form of the (−)-optical isomer. 
   
   
       7 . The composition of  claim 5 , wherein the second anti-hepatitis B agent is famciclovir. 
   
   
       8 . The composition of  claim 5 , wherein the second anti-hepatitis B agent is Bis-POM-PMEA.

Join the waitlist — get patent alerts

Track US2009247487A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.